Optiscan Imaging logo

Optiscan Imaging(ASX) OIL

Market CapA$172.53MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (1997)-15%
5 Year-29%
1 Year+28%
1 Month+7%
A$0.16
-3.03%
-0.00Today
Optiscan Imaging last closing stock price
MetricPriceDate
Last closeAUD 0.162026-10-13
Optiscan Imaging stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-11.11%AUD 0.182026-10-06
1 month+6.67%AUD 0.152026-09-11
3 month+3.23%AUD 0.162026-07-15
Year to date+60%AUD 0.102025-12-31
1 year+28%AUD 0.132025-10-13
3 year+117.7%AUD 0.072023-10-13
5 year-28.52%AUD 0.222021-10-14
Since inception-15.23%AUD 0.191997-08-11

Optiscan Imaging Financials at a Glance

Market Cap

A$172.53MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

A$4.17M

Net Income (TTM)

-A$13.30M

EPS (TTM)

-A$0.01

P/E Ratio

-23.57

Dividend

A$0.00

Beta (Volatility)

0.05 (Low)

Price

A$0.16

Volume

650,244

Open

A$0.17

Previous Close

A$0.16

Daily Range

A$0.15 - A$0.18

52-Week Range

A$0.08 - A$0.20

Estimated Earnings Date

Feb 25, 2026

OIL News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Optiscan Imaging

Optiscan Imaging Limited specializes in confocal microscopy technology, serving clinical and pre-clinical markets globally. The company is known for its innovative FIVE2 (ViewnVivo) system and is developing the InVivage device for cancer screening.

Products and Services
  • FIVE2 (ViewnVivo) system for confocal endomicroscopy
  • InVivage device aimed at cancer screening and surgical applications
  • Research and development services in microscopy technology
Growth Outlook
  • Strong demand for advanced imaging solutions in healthcare
  • Expansion into international markets, including Germany
  • Ongoing development of innovative products to enhance market position
Financial Highlights
  • Recent quarterly revenue of AUD 109,542, showing potential for growth
  • Cash and cash equivalents of AUD 14.35 million, providing operational stability
  • Current ratio of 10.85, indicating strong liquidity position
Optiscan Imaging Limited is positioned in the healthcare sector, focusing on advanced imaging technologies. The company’s flagship product, the FIVE2 system, is designed for a variety of research applications, enhancing its appeal in both clinical and pre-clinical settings. The InVivage device, currently under development, aims to address critical needs in cancer screening and surgical procedures, potentially expanding the company's market reach. The growth outlook for Optiscan is promising, driven by increasing demand for sophisticated imaging solutions and the company's strategic expansion into international markets. The ongoing development of innovative products is expected to further solidify its competitive edge. Financially, the company has demonstrated resilience with a recent quarterly revenue of AUD 109,542, reflecting its ability to generate income despite challenges. A robust cash position of AUD 14.35 million supports operational activities and future growth initiatives. The current ratio of 10.85 indicates a strong liquidity position, allowing the company to meet its short-term obligations effectively. Overall, Optiscan Imaging Limited presents an intriguing opportunity for investors interested in the healthcare technology sector.
AI Generated • Sep 28, 2026

Industry

Healthcare Equipment and Supplies

Sector

Health Care

CEO

Camile Farah, PhD

Website

www.optiscan.com

Headquarters

Mulgrave, VIC 3170, AU

OIL Financials

Key Financial Metrics (TTM)

Gross Margin

-30.37%

Operating Margin

-2191.94%

Net Income Margin

-1556.71%

Return on Equity

-34.10%

Return on Capital

-52.26%

Return on Assets

-31.71%

Earnings Yield

-4.24%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

A$172.53MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

1.05B

Volume

650.24K

Avg. Volume

212.69K

Financials (TTM)

Gross Profit

A$3.12M

Operating Income

-A$16.01M

EBITDA

-A$15.68M

Operating Cash Flow

-A$13.32M

Capital Expenditure

-A$349.07K

Free Cash Flow

-A$13.66M

Cash & ST Invst.

A$14.35M

Total Debt

A$1.34M

Optiscan Imaging Performance Analysis

Optiscan Imaging annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20232023-06-30AUD 1,680,18065.9%
20242024-06-30AUD 1,155,604-31.2%
20252025-06-30AUD 951,948-17.6%
20262026-06-30AUD 448,769-52.9%
Optiscan Imaging sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-12-3127.4%
Q42025-06-30-66.1%
Q22025-12-31-64.1%
Q42026-06-30-67.7%
Optiscan Imaging annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20232023-06-30AUD -0.013.0%
20242024-06-30AUD -0.015.8%
20252025-06-30AUD -0.012.7%
20262026-06-30AUD -0.01-6.7%
Optiscan Imaging sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-12-319.7%
Q42025-06-30-67.9%
Q22025-12-3123.4%
Q42026-06-305.6%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2026YOY CHG

Revenue

A$109.54K

-95.0%

Gross Profit

-A$118.41K

-106.6%

Gross Margin

-1.08%

N/A

Market Cap

A$172.53MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

A$21.57M

N/A

Employees

8

N/A

Net Income

-A$3.59M

-37.9%

EBITDA

-A$4.94M

-90.4%

Quarterly Fundamentals

Name
Q4 2026YOY CHG

Total Cash

A$14.35M

+27.8%

Total Debt

A$1.34M

+508.7%

Accounts Receivable

A$2.85M

+81.5%

Inventory

A$2.35M

+17.4%

Long Term Debt

A$1.17M

N/A

Short Term Debt

A$177.18K

-19.8%

Return on Assets

-31.71%

N/A

Return on Invested Capital

-48.82%

N/A

Free Cash Flow

-A$3.06M

-42.3%

Operating Cash Flow

-A$2.97M

-41.8%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
EMV.AXEMVision Medical Devices Ltd
A$1.64-0.61%
CMP.AXCompumedics Limited
A$0.24-2.04%
MX1.AXMicro-X Limited
A$0.06-4.76%
IBX.AXImagion Biosystems Limited
A$0.01+7.69%

Trending Stocks

Symbol / CompanyPricePrice Chg
ONDSOndas
$6.67-0.89%
INTCIntel
$101.35-3.20%
NOKNokia
$9.90-4.44%
NVDANvidia
$226.32-1.29%

Questions About OIL

What is the current price of Optiscan Imaging?

Optiscan Imaging is trading at A$0.16 per share.

What is the 52-week range for Optiscan Imaging?

Over the past 52 weeks, Optiscan Imaging has traded between A$0.08 and A$0.20.

How much debt does Optiscan Imaging have?

As of the most recent reporting period, Optiscan Imaging reported total debt of A$1.34M.

How much cash does Optiscan Imaging have on hand?

Optiscan Imaging reported A$14.35M in cash and cash equivalents in its most recent financial results.

What is Optiscan Imaging’s dividend yield?

Optiscan Imaging does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services